How do Doximity, Inc. and MANNKIND CORP compare by revenue?

Doximity, Inc. reported revenue of $185.1M in Q3 FY2026, while MANNKIND CORP reported $112.0M in Q4 FY2025. Doximity, Inc. is 1.7× larger by last-quarter revenue.

Which is growing revenue faster, Doximity, Inc. or MANNKIND CORP?

Doximity, Inc.'s latest revenue grew 9.8% year-over-year, versus 45.8% for MANNKIND CORP. MANNKIND CORP is growing faster on a YoY basis.

Which has a higher gross margin, Doximity, Inc. or MANNKIND CORP?

Doximity, Inc.'s gross margin is 89.9% vs MANNKIND CORP's 87.6%. Doximity, Inc. converts more of each revenue dollar into gross profit.

Which has a higher net margin, Doximity, Inc. or MANNKIND CORP?

Doximity, Inc.'s net margin is 33.3% vs MANNKIND CORP's -14.2%. Doximity, Inc. has the higher bottom-line margin.

What is the 2-year revenue CAGR for Doximity, Inc. vs MANNKIND CORP?

Over the trailing 8 quarters, Doximity, Inc. compounded revenue at roughly 25.2% per year, versus 30.0% for MANNKIND CORP. MANNKIND CORP has the faster medium-term growth trajectory.

Where does this DOCS vs MNKD data come from?

All figures are parsed directly from SEC EDGAR 10-Q / 10-K / 20-F / 6-K filings (for US-listed issuers) or EDINET filings (for Japanese issuers), then normalised into a common schema. Numbers update automatically as new filings are released.

vs

Side-by-side financial comparison of Doximity, Inc. (DOCS) and MANNKIND CORP (MNKD). Click either name above to swap in a different company.

Doximity, Inc. is the larger business by last-quarter revenue ($185.1M vs $112.0M, roughly 1.7× MANNKIND CORP). Doximity, Inc. runs the higher net margin — 33.3% vs -14.2%, a 47.5% gap on every dollar of revenue. On growth, MANNKIND CORP posted the faster year-over-year revenue change (45.8% vs 9.8%). Over the past eight quarters, MANNKIND CORP's revenue compounded faster (30.0% CAGR vs 25.2%).

Doximity, Inc.DOCSEarnings & Financial Report

NYSE · Information Technology · Services-Computer Programming Services

Doximity is an online networking service for medical professionals. Launched in 2010, the platform offers its members curated medical news, telehealth tools, and case collaboration.

MANNKIND CORPMNKDEarnings & Financial Report

Nasdaq · Health Care · Pharmaceutical Preparations

MannKind Corporation is a biopharmaceutical company focusing on the discovery, development, and commercialization of therapeutic products for diseases such as diabetes and pulmonary arterial hypertension. Based in Danbury, Connecticut, the company was founded in February 1991.

DOCS vs MNKD — Head-to-Head

Bigger by revenue

DOCS

1.7× larger

$185.1M

$112.0M

Growing faster (revenue YoY)

MNKD

+36.1% gap

45.8%

9.8%

Higher net margin

DOCS

47.5% more per $

33.3%

-14.2%

Faster 2-yr revenue CAGR

MNKD

Annualised

30.0%

25.2%

Income Statement — Q3 FY2026 vs Q4 FY2025

Metric	DOCS	MNKD
Revenue	$185.1M	$112.0M
Net Profit	$61.6M	$-15.9M
Gross Margin	89.9%	87.6%
Operating Margin	38.9%	-6.9%
Net Margin	33.3%	-14.2%
Revenue YoY	9.8%	45.8%
Net Profit YoY	-18.1%	-314.9%
EPS (diluted)	$0.31	$-0.05

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue

DOCS

MNKD

Q4 25	$185.1M	$112.0M
Q3 25	$168.5M	$82.1M
Q2 25	$145.9M	$76.5M
Q1 25	$138.3M	$78.4M
Q4 24	$168.6M	$76.8M
Q3 24	$136.8M	$70.1M
Q2 24	$126.7M	$72.4M
Q1 24	$118.1M	$66.3M

Net Profit

DOCS

MNKD

Q4 25	$61.6M	$-15.9M
Q3 25	$62.1M	$8.0M
Q2 25	$53.3M	$668.0K
Q1 25	$62.5M	$13.2M
Q4 24	$75.2M	$7.4M
Q3 24	$44.2M	$11.6M
Q2 24	$41.4M	$-2.0M
Q1 24	$40.6M	$10.6M

Gross Margin

DOCS

MNKD

Q4 25	89.9%	87.6%
Q3 25	90.3%	94.5%
Q2 25	89.2%	94.0%
Q1 25	89.5%	95.2%
Q4 24	91.6%	93.7%
Q3 24	90.0%	95.4%
Q2 24	89.3%	92.3%
Q1 24	89.4%	94.2%

Operating Margin

DOCS

MNKD

Q4 25	38.9%	-6.9%
Q3 25	37.8%	23.0%
Q2 25	37.4%	6.9%
Q1 25	35.2%	28.5%
Q4 24	47.4%	34.5%
Q3 24	38.8%	18.2%
Q2 24	36.4%	22.9%
Q1 24	35.5%	25.2%

Net Margin

DOCS

MNKD

Q4 25	33.3%	-14.2%
Q3 25	36.8%	9.7%
Q2 25	36.5%	0.9%
Q1 25	45.2%	16.8%
Q4 24	44.6%	9.7%
Q3 24	32.3%	16.5%
Q2 24	32.7%	-2.8%
Q1 24	34.4%	16.0%

EPS (diluted)

DOCS

MNKD

Q4 25	$0.31	$-0.05
Q3 25	$0.31	$0.03
Q2 25	$0.27	$0.00
Q1 25	$0.31	$0.04
Q4 24	$0.37	$0.03
Q3 24	$0.22	$0.04
Q2 24	$0.21	$-0.01
Q1 24	$0.20	$0.04

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric	DOCS	MNKD
Cash + ST InvestmentsLiquidity on hand	$64.8M	$171.3M
Total DebtLower is stronger	—	$354.6M
Stockholders' EquityBook value	$979.3M	$-51.0M
Total Assets	$1.2B	$792.2M
Debt / EquityLower = less leverage	—	—

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments

DOCS

MNKD

Q4 25	$64.8M	$171.3M
Q3 25	$169.2M	$260.0M
Q2 25	$137.3M	$179.0M
Q1 25	$209.6M	$181.5M
Q4 24	$165.3M	$197.3M
Q3 24	$184.2M	$251.6M
Q2 24	$111.4M	$247.8M
Q1 24	$96.8M	$300.7M

Total Debt

DOCS

MNKD

Q4 25	—	$354.6M
Q3 25	—	$109.7M
Q2 25	—	$36.2M
Q1 25	—	$36.1M
Q4 24	—	$36.1M
Q3 24	—	$227.9M
Q2 24	—	$227.6M
Q1 24	—	$264.1M

Stockholders' Equity

DOCS

MNKD

Q4 25	$979.3M	$-51.0M
Q3 25	$1.1B	$-44.6M
Q2 25	$1.0B	$-55.0M
Q1 25	$1.1B	$-58.6M
Q4 24	$1.0B	$-78.8M
Q3 24	$961.2M	$-209.9M
Q2 24	$913.6M	$-225.8M
Q1 24	$901.4M	$-230.0M

Total Assets

DOCS

MNKD

Q4 25	$1.2B	$792.2M
Q3 25	$1.3B	$494.6M
Q2 25	$1.2B	$411.7M
Q1 25	$1.3B	$410.1M
Q4 24	$1.2B	$393.8M
Q3 24	$1.1B	$464.2M
Q2 24	$1.1B	$443.8M
Q1 24	$1.1B	$480.9M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric	DOCS	MNKD
Operating Cash FlowLast quarter	$60.9M	$-8.0M
Free Cash FlowOCF − Capex	—	$-10.0M
FCF MarginFCF / Revenue	—	-8.9%
Capex IntensityCapex / Revenue	—	1.8%
Cash ConversionOCF / Net Profit	0.99×	—
TTM Free Cash FlowTrailing 4 quarters	—	$13.7M